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Abstract Children with chronic kidney disease (CKD) are
at risk for “cachexia” or “protein-energy wasting” (PEW).
These terms describe a pathophysiologic process resulting
in the loss of muscle, with or without loss of fat, and
involving maladaptive responses, including anorexia and
elevated metabolic rate. PEW has been defined specifically
in relation to CKD. We review the diagnostic criteria for
cachexia and PEW in CKD and consider the limitations and
applicability of these criteria to children with CKD. In
addition, we present an overview of the manifestations and
mechanisms of cachexia and PEW. A host of pathogenetic
factors are considered, including systemic inflammation,
endocrine perturbations, and abnormal neuropeptide signal-
ing, as well as poor nutritional intake. Mortality risk, which
is 100- to 200-fold higher in patients with end-stage renal
disease than in the general population, is strongly correlated
with the components of cachexia/PEW. Further research
into the causes and consequences of wasting and growth
retardation is needed in order to improve the survival and
quality of life for children with CKD.
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Introduction
Surveys using traditional measures of nutritional status
indicate that wasting is common among adults with chronic
kidney disease (CKD), with 20–75% of adults undergoing
maintenance dialysis showing some evidence of wasting [1,
2]. At present, only limited data are available on the
prevalence of wasting in children with CKD. The accumu-
lation of new evidence and novel thinking in the field of
nutrition in CKD has resulted in a recent redefinition of
commonly used terms. Wasting caused by factors other than
inadequate intake alone is sometimes referred to as
cachexia. Cachexia was recently defined as “a complex
metabolic syndrome associated with underlying illness and
characterized by loss of muscle, with or without loss of fat”,
by a group of scientists and clinicians participating in a
consensus conference on cachexia [3]. This group, which
later formed the Society for Cachexia and Wasting
Disorders (SCWD) and included participants with diverse
backgrounds encompassing many of the diseases states that
result in cachexia (such as cancer, human immunodeficien-
cy virus infection, heart failure, CKD, and chronic
obstructive pulmonary disease), identified weight loss and
growth failure as the most important clinical features of
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cachexia in adults and children, respectively. In the context
of CKD, the term protein-energy wasting (PEW) has been
proposed by The International Society of Renal Nutrition
and Metabolism (ISRNM) to describe a “state of decreased
body stores of protein and energy fuels (body protein and
fat masses)” [4]. The ISRNM suggested that the term
cachexia be reserved for only the most severe forms of
PEW. However, there is no obvious distinction between
PEW and cachexia from a pathophysiology standpoint;
limiting the term cachexia to extreme forms of PEW is
perhaps too restrictive.
Cachexia/wasting or malnutrition in CKD
Wasting, defined as low weight for height [5], was once
believed to be invariably caused by inadequate nutritional
intake—or malnutrition. As a result, the terms, “wasting”,
“cachexia”, and “malnutrition” were generally used inter-
changeably, which has caused confusion. Although inade-
quate nutritional intake may contribute to cachexia or PEW,
recent evidence indicates that other factors, including
systemic inflammation, endocrine perturbations, and abnor-
mal neuropeptide signaling, may play important roles in
wasting in the context of CKD [1, 6–10]. The cachexia/
wasting syndrome is characterized by maladaptive
responses, including anorexia and increased metabolic rate,
and is associated with low serum albumin and loss of body
weight; muscle mass is reduced, whereas fat mass is normal
or increased. In contrast, malnutrition, defined as the
consequence of insufficient food or an improper diet, is
characterized by adaptive responses, including hunger, a
protective decrease in energy expenditure, and preferential
use of fat stores for energy and preservation of lean body
mass. Whereas the abnormalities in malnutrition are usually
easily reversed by supplying more food or altering the
composition of the diet, these approaches are generally
unsuccessful in treating cachectic patients [11]. Distinctions
between cachexia and malnutrition are summarized in
Table 1.
Clinical features and diagnostic criteria of cachexia/
PEW in CKD
The diagnostic criteria for cachexia (proposed by the
SCWD) and for PEW (proposed by the ISRNM) are
similar, but not identical. A weight loss of at least 5% over
12 months or less or a body mass index (BMI) <20 kg/m2 is
necessary for the diagnosis of cachexia, plus three of the
following five additional criteria: decreased muscle
strength, fatigue, anorexia, low fat-free muscle mass, and
abnormal biochemistry [including elevated inflammatory
markers such as C-reactive protein (CRP) or interleukin
(IL)-6, anemia (hemoglobin<12 g/dL) and hypoalbumine-
mia]. The proposed criteria for a diagnosis of PEW fall into
four distinct categories: (1) biochemical indicators; (2) low
body weight, reduced body fat, or weight loss; (3)
decreased muscle mass; (4) low protein or energy intake.
In contrast to those for PEW, the diagnostic criteria for
cachexia emphasize lean mass deficits and functional
measures (such as muscle strength and fatigue); in addition,
anemia is considered a feature of cachexia, but not of PEW.
Table 2, reprinted from the recent consensus paper defining
PEW in adult CKD, lists potential PEW markers [4].
Both sets of diagnostic criteria are based largely on
evidence in adults and are, therefore, geared towards adults.
Modifications to these diagnostic criteria are necessary to
improve their applicability to children. In this review, we
focus on PEW because this concept was developed to be
specifically applicable to CKD patients. The common
pathophysiology of PEW and cachexia is acknowledged.
The proposed diagnostic criteria for PEW, their limitations,
and possible pediatric modifications are discussed.
Biochemical indicators
Among the biochemical indicators of PEW, low serum
albumin stands out as a consistent predictor of mortality in
epidemiological studies of both adult [12] and pediatric
[13] dialysis patients. However, the specificity of serum
albumin as an indicator of PEW in the setting of CKD is
not assured [14–21]. Both volume overload and systemic
inflammation are associated with depressed serum albumin
[17, 18]. In the absence of inflammatory markers, hypo-
albuminemia is not predictive of increased mortality [20,
21]. Hypoalbuminemia was noted by the ISRNM commit-
tee to be neither necessary nor sufficient for a diagnosis of
PEW. However, given its strong association with mortality,
hypoalbuminemia is considered an important biochemical
indicator of PEW; its presence should prompt careful
assessment of volume status and an investigation for causes
of systemic inflammation. Serum prealbumin (also known
as transthyretin) has also been recommended as a marker of
PEW in dialysis patients; the limitations of prealbumin are
Table 1 Comparison of malnutrition and cachexia/PEW
Characteristics Malnutrition Cachexia/PEW
Energy balance − −
Appetite ↑ ↓
Metabolic rate ↓ ↑
Muscle mass ≈ ↓
Fat mass ↓ ≈
Response to calorie supplementation + −
PEW, Protein-energy wasting
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similar to those of albumin. A recent study in adult
hemodialysis patients suggested that although baseline serum
prealbumin level may not be superior to serum albumin in
predicting mortality, prealbumin concentrations <20 mg/dL
are associated with death risk even in normoalbuminemic
patients, and a fall in serum prealbumin over a 6-month period
is independently associated with increased death risk [4].
Other nutritional indicators that predict survival in dialysis
patients include serum transferrin level [22] and nutritional
scoring systems, such as the “subjective global asses-
sment”(SGA) [23] and “malnutrition inflammation score”.
These scores also correlate with quality of life [24, 25]. Low
serum cholesterol has also been proposed as a biochemical
indicator of PEW due to its association with mortality in
adults with CKD [26]. There are no data on associations
between low cholesterol and outcomes in children with
CKD; future studies that account for the normal variation in
serum cholesterol levels with age [27] and characterize
associations between low cholesterol and poor outcomes
(death, growth failure) are needed before cholesterol levels
can be included in the diagnostic criteria for PEW in
children. Circulating inflammatory markers such as CRP
[28] and pro-inflammatory cytokines such as IL-6 [29] are
persistently elevated in PEW and may be predictive of
mortality—but were not included as part of the diagnostic
criteria of PEW.
Low body weight, weight loss, or reduced body fat
Evidence of low body weight, reduced body fat, or weight
loss are important indicators of PEW in adults. BMI,
calculated as weight (kg) divided by height squared (m2), is
proposed as a method of assessing the appropriateness of
body weight. Although BMI gives little information about
body composition, it can be a useful means of assessing
PEW. BMI is strongly correlated with lean body mass at the
low end of the BMI spectrum [30], and low BMI is a
consistent predictor of mortality in both adults [31, 32] and
children [33] on maintenance dialysis. Because BMI
normally changes with growth and development, it must
Table 2 Readily utilizable criteria for the clinical diagnosis of PEW in adults with chronic kidney disease
Criteria for PEW
Serum chemistry
Serum albumin <3.8 g per 100 ml (Bromocresol Green)a
Serum prealbumin (transthyretin) <30 mg per 100 ml (for maintenance dialysis patients only; levels may vary according to GFR level for
patients with CKD stages 2–5)a
Serum cholesterol <100 mg per 100 mla
Body mass
BMI <23b
Unintentional weight loss over time: 5% over 3 months or 10% over 6 months
Total body fat percentage <10%
Muscle mass
Muscle wasting: reduced muscle mass 5% over 3 months or 10% over 6 months
Reduced mid-arm muscle circumference areac (reduction >10% in relation to 50th percentile of reference population)
Creatinine appearanced
Dietary intake
Unintentional low DPI <0.80 g kg−1 day−1 for at least 2 monthse for dialysis patients or <0.6 g kg−1 day−1 for patients with CKD stages 2–5
Unintentional low DEI <25 kcal kg−1 day−1 for at least 2 monthse
Reproduced from Fouque et al. [4] with permission from Macmillian Publishers
GFR, Glomerular filtration rate; CKD, chronic kidney disease; BMI, body mass index; DPI, dietary protein intake; DEI, dietary energy intake;
nPCR, normalized protein catabolic rate; nPNA, normalized protein nitrogen appearance
At least three out of the four listed categories (and at least one test in each of the selected category) must be satisfied for the diagnosis of kidney
disease-related PEW. Optimally, each criterion should be documented on at least three occasions, preferably 2–4 weeks apart
a Not valid if low concentrations are due to abnormally great urinary or gastrointestinal protein losses, liver disease, or cholesterol-lowering medicines.
b A lower BMI might be desirable for certain Asian populations; weight must be edema-free mass, for example, post-dialysis dry weight. See text for the
discussion about the BMI of the healthy population
cMeasurement must be performed by a trained anthropometrist
d Creatinine appearance is influenced by both muscle mass and meat intake
e Can be assessed by dietary diaries and interviews, or for protein intake by calculation of normalized protein equivalent of total nitrogen appearance (nPNA
or nPCR) as determined by urea kinetic measurements
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be expressed in children as a percentile or Z score relative
to age and sex. BMI-for-age percentiles and Z scores can be
determined using sex-specific BMI-for-age growth curves
from the Centers for Disease Control (updated in 2000) [34]
for children ≥2 years of age and the 2006 World Health
Organization Child Growth Standards for children <2 years
of age [35]. In the setting of CKD, it has been suggested
that BMI should be expressed relative to height–age (the
age at which the child’s height would be at the 50%
percentile), rather than chronological age, due to the high
prevalence of growth retardation and delayed sexual
maturation [36]. Regardless of how BMI is expressed, it
is difficult to set a BMI percentile cut-off below which a
diagnosis of PEW should be considered for children with
CKD. Underweight is defined by the American Centers for
Disease Control as a BMI below the 5th percentile for age
[37, 38]. However, this cut-off may not be appropriate as a
criterion for PEW in children with CKD. Existing evidence
suggests that a higher cut-off may be more appropriate [33],
but definitive data are lacking.
An unintentional weight loss or reduction in weight
of ≥5% over a 3-month period or of ≥10% over a 6-
month period is suggested as an indicator of PEW in
adults, independent of absolute BMI [4]. In children,
weight loss is an insensitive indication of PEW; a more
appropriate diagnostic criterion would be failure to gain
weight appropriately, as evidenced by a crossing-down of
BMI percentiles. Linear growth failure has been high-
lighted as being central to the diagnosis of cachexia [3]
and has been associated with a greater mortality risk in
infants [39] and children [33] with CKD. However,
although growth retardation may be a feature of PEW or
cachexia in children, it should be recognized that failure
to grow does not always indicate “wasting” in CKD.
Growth failure in CKD has several causes, including
inadequate calorie intake, delayed sexual maturation, and
growth hormone insensitivity. Growth failure may emerge
as a necessary, but not sufficient criterion for PEW or
cachexia in children with CKD.
A body fat mass of <10% of body weight is considered
to be an additional criterion for PEW in adults with CKD
[4] due to the known association between a total body fat
<10% and increased mortality risk in adult maintenance
dialysis patients [40]. However, like BMI, percentage body
fat changes with growth and development in healthy
children. Therefore, a single percent body fat cut-off cannot
be used as a criterion for PEW in children. In addition,
percent body fat may be difficult to interpret in conditions
where abnormalities in both fat and lean mass may be
present; a decrease in lean mass will result in an apparent
increase in percent fat, even if there is no real change in fat
mass. Furthermore, studies linking low percent fat to poor
outcomes in children with CKD are lacking.
Decreased muscle mass
Reduced muscle mass appears to be the most valid criterion
for the presence of PEW in CKD [4], and is also emphasized
in the diagnostic criteria for cachexia [3]. Muscle mass,
measured using dual energy X-ray absorptiometry (DXA),
has been observed to be low in children [41] with CKD.
Similar findings have been shown in adults with CKD using
near-infrared interactance and bioelectrical impedance [42].
However, such techniques are not practical in the clinical
setting. There is currently no clinically useful and reproduc-
ible method of measuring muscle mass. Accurate assessment
of the adequacy of muscle mass is even more challenging in
infants and children, in whom all measures must be
normalized for body size and stage of sexual maturation
[15]. Indirect measures, such as creatinine appearance
(estimated by quantification of creatinine in a 24-h urine
collection and in the collected spent dialysate), have been
proposed as an index of muscle mass in adults with CKD
[4]. However, reference values for creatinine appearance are
not available for children, making interpretation impossible
at present.
Low protein or energy intake
Diminished appetite (anorexia), one of the suggested criteria
for PEW (and for cachexia), has been associated with
increased mortality in adult dialysis patients [43]. Anorexia
is a common feature of CKD in infants and is the primary
reason for growth failure in this group [44–47]. Poor growth
due to inadequate intake has been observed in infants with a
glomerular filtration rate (GFR) as high as 70 ml min−1 1.73
m−2 [44]. The prevalence of anorexia among children with
CKD beyond infancy is unknown. There is ample evidence
to support the effectiveness of supplemental calories in
promoting growth in children with CKD up to about 2 years
of age [48]. However, calorie intake is generally appropriate
for body size in older children with CKD, and there is no
evidence that supplemental calories promote growth in the
older age group [49]
The validity of the proposed diagnostic criteria for PEW
are as yet unconfirmed, even for adults. Nonetheless, it
would be useful to develop analogous consensus criteria
specifically for infants and children, which could then be
validated in prospective, longitudinal studies.
Pathophysiology of cachexia/PEW syndrome in CKD
The pathophysiology of cachexia/PEW syndrome in CKD is
multifactorial; Fig. 1 provides an overview. For the purpose
of this review, we will focus on three major features:
anorexia, increased energy expenditure, and muscle wasting.
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Anorexia
Anorexia in CKD patients is caused by a combination of
factors, including altered taste [50], gastroesophageal reflux,
delayed gastric emptying, and elevated levels of numerous
cytokines, including IL-1, IL-6, and tumor necrosis factor
(TNF)-α [51]. Perturbations in appetite-regulating hormones,
such as leptin [52] and ghrelin [53], may contribute to
anorexia in CKD. Leptin is degraded by the kidney. As a
result, circulating leptin concentrations are strongly and
inversely correlated with GFR in children [54]. Experimental
uremic anorexia can be improved by leptin signaling blockade
through the hypothalamic melanocortin-4 receptor by the
addition of agouti-related peptide (AgRP), a melanocortin
reverse agonist, suggesting a possible future therapeutic
strategy for PEW in CKD [55, 56]. Human data on leptin
and CKD–PEW are so far inconclusive. Hyperleptinemia was
not associated with anorexia in adult dialysis patients [57],
and expressing leptin levels relative to body weight resulted in
the obliteration of apparent leptin-related differences in
degrees of anorexia and caloric intake between CKD patients
[58]. It has consequently been suggested that the hyper-
leptinemia associated with CKD is mitigated by the decrease
in leptin that results from the loss of body fat mass in
anorectic patients. As a result, any links between leptin and
appetite are obscured in this population [59].
The kidney also degrades ghrelin. However, total ghrelin
levels are not consistently elevated in CKD, despite the
decreased degradation of ghrelin by the kidney [53, 60].
Whereas in some studies elevated ghrelin levels were found
in dialysis patients, in other studies, the levels were normal
or even low [61–63]. Multiple confounding factors may
contribute to these seemingly contradicting findings. The
two major forms of circulating ghrelin are acylated (<10%)
and des-acyl ghrelin [64, 65]. Acylated ghrelin promotes
food intake while des-acyl ghrelin induces negative energy
balance. Most investigators used the traditional radioimmu-
noassay method to quantify total (acylated plus des-acyl)
ghrelin. However, only des-acyl ghrelin levels were
elevated in CKD patients compared with individuals with
normal renal function. Elevated des-acyl ghrelin has been
implicated in CKD-related anorexia [65]. Age, sex, and
nutritional status may also influence plasma ghrelin levels
[59, 62, 66]. Most studies of CKD patients did not account
for abnormalities in nutritional status. Furthermore,
nutrients introduced during dialysis (i.e., glucose, amino
acids) may also influence plasma ghrelin levels [67]. Future
longitudinal studies, in which changes in serum acyl- and
des-acyl ghrelin levels (measured using enzyme-linked
immunosorbent assay) [68] and concomitant nutritional
status are measured over time, are needed to determine the
pathophysiologic role of ghrelin in CKD [69].
Fig. 1 Schematic representation of the causes and manifestations of the
protein–energy wasting (PEW) syndrome in chronic kidney disease
(CKD). GH Growth hormone, IGF insulin-like growth factor, PTH
parathyroid hormone. Modified from Fouque et al. [4], reprinted with
permission from Macmillian Publishers
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Increased energy expenditure
Increased energy expenditure despite inadequate calorie
intake is an important feature of cachexia often observed in
CKD. Wang et al. [70] reported elevated resting energy
expenditure (REE) in adults on peritoneal dialysis, with
REE predicting subsequent mortality. However, the signif-
icance of REE in predicting mortality was gradually
reduced when additional adjustment was made for CRP,
serum albumin, and residual GFR in a stepwise manner
[70].
Increased REE in CKD may be due to increased activity
of mitochondrial uncoupling proteins (UCPs). UCPs, a
family of mitochondrial anion transporters, regulate ATP
synthesis and the production of reactive oxygen species.
Uncoupling of mitochondrial electron transporter chain
activity from the phosphorylation of ADP results in
thermogenesis [71]. UCP-1 and UCP-3 are key regulators
of energy expenditure in rodents [72] and humans [73]. In a
previous investigation, we showed that uremic mice had a
higher basal metabolic rate and associated elevations in
brown adipose tissue UCP-1 mRNA and protein and UCP-
3 protein content compared with pair-fed control mice [74].
Muscle wasting
There is evidence that inflammation is an important cause
of muscle wasting in CKD. In animal studies, infusion of
cytokines, such as TNF-α, IL-6, IL-1β, and interferon-
gamma (IFN-γ), enhanced muscle protein degradation via
the NFκβ pathway [75, 76], whereas neutralization of these
factors by genetic or pharmacological approaches attenuates
muscle wasting. Inflammation activates the ubiquitin–
proteasome system, which leads to increased muscle
breakdown [77] that is not countered by a corresponding
upregulation of anabolic pathways [78] (Fig. 2).
NFκβ is a central integration molecule for pro-
inflammatory signals and a regulator of related target
genes. As such, NFκβ activation is required for cytokine-
induced loss of skeletal muscle proteins. TNF-α induces
NFκβ activation, which attenuates insulin-stimulated pro-
tein synthesis, leading to muscle wasting. TNF-α also
inhibits myocyte differentiation through NFκβ activation,
further promoting muscle wasting. Activation of NFκβ
signaling is sufficient to induce significant muscle atrophy,
as measured by increases in amino acid excretion and
tyrosine turnover in isolated muscles [79]. Activation of
NFκβ is controlled by Iκβ kinase complex (IKK).
Furthermore, inflammation may suppress insulin signaling
and increase the production of glucocorticoids [51].
Myostatin and insulin-like growth factor 1 (IGF-1)
represents yin and yang signaling pathways in the patho-
genesis of muscle wasting in CKD [80]. Myostatin, which
circulates in a latent form that can be activated by acid
treatment, downregulates skeletal muscle mass. Myostatin-
deficient mice show muscle fiber hyperplasia and hyper-
trophy, resulting in a marked increase in muscle mass [81].
In contrast, systemic overexpression of myostatin in adult
mice induced profound muscle and fat loss analogous to
that seen in human cachexia syndromes [82]. Thus,
myostatin may act as a muscle “chalone,” a term proposed
over 30 years ago for a circulating protein that inhibits the
growth of a particular tissue and thereby maintains
appropriate tissue mass [82].
IGF-1 is also essential for the growth and maintenance
of skeletal muscle mass. Both IGF-1 and IGF-1 receptor
knockout mice were significantly smaller than their control
littermates and had reduced muscle mass, whereas overex-
pressed IGF-1 transgenic mice showed increased muscle
mass [83]. Growth retardation and muscle wasting in CKD
are associated with perturbations in the growth hormone–
IGF-1 axis [84]. Treatment of children with CKD with
recombinant human GH has been identified as an important
and significant determinant of higher muscle mass relative
to height [41]. This finding emphasizes the potential
importance of IGF-1 in the pathogenesis of muscle wasting
in CKD. The balance between expression of myostatin and
IGF-1 is important in regulating muscle mass in CKD [80].
Conclusion
Many questions remain regarding the description, classifica-
tion, and treatment of PEWor cachexia in children with CKD.
Can nutritional intervention improve the biochemical and



























Fig. 2 Pathophysiology of muscle wasting in CKD. Reprinted from
Cheung et al. [78] with permission from Macmillian Publishers
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are effective at improving indicators of PEW, will clinical
outcomes also improve? Our new understanding of the
pathophysiology of PEW in CKD has the promise of novel
therapeutic strategies. Novel therapies, such as ghrelin
agonists [85] and melanocortin antagonists [51], are poten-
tially exciting new strategies. However, most of the
information is currently at the experimental level and awaits
confirmation by randomized controlled clinical trials in
children with CKD-associated cachexia/PEW syndrome.
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